Seven prognostic factors associated with poor DMFS after ILRR among patients with breast cancer were identified: ILRR receptor status (ER-positive/PR-negative/HER2-negative tumor), shorter DFI (DFI shorter than 48 months), recurrence site (chest wall recurrence with or without regional node, and isolated regional node recurrence), non-resection of ILRR, nodal stage in the primary tumor (N2 or N3), CT for the primary tumor, and no ET for the ILRR. This evidence concerns the gene PGR and breast carcinoma.